Adagene Inc Adr stock is traded at $2.02, with a volume of 345,329. It is down -16.18% in the last 24 hours and down -31.06% over the past month. Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
Previous Close:
$2.41
Open:
$2.24
24h Volume:
345,329
Relative Volume:
2.05
Market Cap:
$135.63M
Revenue:
$7.69M
Net Income/Loss:
-$17.65M
P/E Ratio:
-
EPS:
-$0.3743
Net Cash Flow:
-$15.72M
1W Performance:
-19.52%
1M Performance:
-31.06%
6M Performance:
-44.04%
1Y Performance:
+25.47%
1-Day Range:
$0.00$0.00
1-Week Range:
$2.01$2.60
52-Week Range:
$1.30$4.85
Adagene Inc Adr Stock (ADAG) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS